Advertisement

MMW - Fortschritte der Medizin

, Volume 161, Issue 3, pp 50–57 | Cite as

Menopause

Auf gutem Weg durch die Wechseljahre

  • Corinna MannEmail author
  • Sven Mahner
  • Christian J. Thaler
FORTBILDUNG . ÜBERSICHT
  • 554 Downloads

Zusammenfassung

Reproduktives Altern und Menopause werden aus der gesellschaftlichen Wahrnehmung immer noch weitgehend ausgeblendet und stattdessen wird ein Bild dauerhaft junger, aktiver und fruchtbarer Frauen gezeichnet. Umso belastender sind der Verlust der Fertilität, das Altern und der Beginn einer anderen Lebensphase für viele Frauen, zumal sie sich oft mit diesen Themen alleingelassen fühlen. Ergreifen Sie die Gelegenheit und sprechen Sie mit Ihren betroffenen Patientinnen!

Menopause

Keywords

Vasomotor symptoms hormonal changes hormone therapy reproductive aging 

Literatur

  1. 1.
    de Bruin JP, Bovenhuis H, van Noord PA et al. The role of genetic factors in age at natural menopause. Hum Reprod. 001;16:2014–18Google Scholar
  2. 2.
    Cooper GS, Sandler DP. Age at natural menopause and mortality. Ann Epidemiol. 1998;8:229–35CrossRefGoogle Scholar
  3. 3.
    Wise AM, Krajnak KM, Kashon ML. Menopause: the aging of multiple pacemakers. Science. 1996;273:67–70CrossRefGoogle Scholar
  4. 4.
    Snowdon DA, Kane RL, Besson WL et al. Is early natural menopause a biologic marker of health and aging? Am J Public Health. 1989;79:709–14CrossRefGoogle Scholar
  5. 5.
    Stanford L, Hartge P, Brinton LA et al. Factors influencing the age at natural menopause. J Chronic Dis. 1987;40:995–1002CrossRefGoogle Scholar
  6. 6.
    van Noord PA, Dubas JS, Dorland M et al. Age at natural menopause in a population-based screening cohort: the role of menarche, fecundity, and lifestyle factors. Fertil Steril. 1997;68:95–102CrossRefGoogle Scholar
  7. 7.
    Ahuja M. Age of menopause and determinants of menopause age: a PAN India survey by IMS. J Midlife Health. 2016;7:126–31PubMedPubMedCentralGoogle Scholar
  8. 8.
    Turner G, Robinson H, Wake S et al. Dizygous twinning and pre-mature menopause in fragile X syndrome. Lancet. 1994;344:1500CrossRefGoogle Scholar
  9. 9.
    Conway GS, Hettiarachchi S, Murray A et al. Fragile X permutations in familial premature ovarian failure. Lancet. 1995;346:309–10CrossRefGoogle Scholar
  10. 10.
    Burger HG, Dudley EC, Robertson DM et al. Hormonal changes in the menopause transition. Recent Prog Horm Res. 2002;57:257–75CrossRefGoogle Scholar
  11. 11.
    Santoro N, Adel T, Skurnick JH. Decreased inhibin tone and increased activin A secretion characterize reproductive aging in women. Fertil Steril. 1999;71:658–62CrossRefGoogle Scholar
  12. 12.
    Santoro N, Lasley B, McConnell D et al. Body size and ethnicity are associated with menstrual cycle alterations in women in the early menopausal transition: the study of women’s health across the nation (SWAN) daily hormone study. J Clin Endocrinol Metab. 2004;89:2622–31CrossRefGoogle Scholar
  13. 13.
    Santoro N, Brown JR, Adel T et al. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab. 1996;81:1495–1501PubMedGoogle Scholar
  14. 14.
    JF Randolph Jr, Zheng H, MR Sowers et al. Change in follicle-stimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period. J Clin Endocrinol Metab. 2011;96:746–54CrossRefGoogle Scholar
  15. 15.
    Santoro N. Using antimullerian hormone to predict fertility. JAMA. 2017;318:1333–4CrossRefGoogle Scholar
  16. 16.
    Soules MR, Sherman S, Parrott E, Rebar R, Santoro N, Utian W, Woods N. Executive summary: Stages of reproductive aging workshop (STRAW). Fertil Steril. 2001;76:874–8CrossRefGoogle Scholar
  17. 17.
    Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ. STRAW + 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012;97:1159–68CrossRefGoogle Scholar
  18. 18.
    Stuenkel CA, Davis SR, Gompel A et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:3975–4011CrossRefGoogle Scholar
  19. 19.
    Gallicchio L, Miller SR, Kiefer J et al. Risk factors for hot flashes among women undergoing the menopausal transition: baseline results from the midlife women’s health study. Menopause. 2015;22:1098–1107CrossRefGoogle Scholar
  20. 20.
    Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med. 2009;6:2133–42CrossRefGoogle Scholar
  21. 21.
    Kravitz HM, Joffe H. Sleep during the perimenopause: a SWAN story. Obstet Gynecol Clin North Am. 2011;38:567–86CrossRefGoogle Scholar
  22. 22.
    Bromberger JT, Kravitz HM. Mood and men-opause: findings from the study of women’s health across the nation (SWAN) over 10 years. Obstet Gynecol Clin North Am. 2011;38:609–25CrossRefGoogle Scholar
  23. 23.
    Cohen LS, Soares CN, Vitonis AF et al. Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. Arch Gen Psychiatry. 2006;63:385–90CrossRefGoogle Scholar
  24. 24.
    Freeman EW, Sammel MD, Lin H et al. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry. 2006;63:375–82CrossRefGoogle Scholar
  25. 25.
    van Voorhis BJ, Santoro N, Harlow S et al. The relationship of bleeding patterns to daily reproductive hormones in women approaching menopause. Obstet Gynecol. 2008;112:101–8CrossRefGoogle Scholar
  26. 26.
    Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB, Hess R, Joffe H, Kravitz HM, Tepper PG, Thurston RC. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175:531–9CrossRefGoogle Scholar
  27. 27.
    Sarrel P1, Portman D, Lefebvre P, Lafeuille MH, Grittner AM, Fortier J, Gravel J, Duh MS, Aupperle PM. Incremental direct and indirect costs of untreated vasomotor symptoms. Menopause. 2015;22:260–6CrossRefGoogle Scholar
  28. 28.
    Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O’Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S, Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291:1701–12CrossRefGoogle Scholar
  29. 29.
    Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA.2002;288:321–33CrossRefGoogle Scholar
  30. 30.
    Gesundheitsreport der Techniker Krankenkasse 2011Google Scholar
  31. 31.
    Rossouw JE1, Manson JE, Kaunitz AM, Anderson GL. Lessons learned from the Women’s Health Initiative trials of menopausal hormone therapy. Obstet Gynecol. 2013;121:172–6CrossRefGoogle Scholar
  32. 32.
    Manson JE, Kaunitz AM. Menopause management — Getting clinical care back on track. N Engl J Med. 2016;374:803–6CrossRefGoogle Scholar
  33. 33.
    Santen RJ, Stuenkel CA, Burger HG, Manson JE. Competency in menopause management: whither goest the internist? J Womens Health 2014;23:281–5CrossRefGoogle Scholar
  34. 34.
    Mueck AO. Anwendungsempfehlungen zur Hormonsubstitution im Klimakterium und Postmenopause. Frauenarzt 2015;56:657–9Google Scholar
  35. 35.
    Bassuk SS, Manson JE. The timing hypothesis: Do coronary risks of menopausal hormone therapy vary by age or time since menopause onset? Metabolism. 2016;65:794–803CrossRefGoogle Scholar
  36. 36.
    Hodis HN, Mack WJ, Shoupe D, Azen SP, Stanczyk FZ, Hwang-Levine J, Budoff MJ, Henderson VW. Methods and baseline cardiovascular data from the Early versus Late Intervention Trial with Estradioltesting the menopausal hormone timing hypothesis. Menopause. 2015;22:391–401CrossRefGoogle Scholar
  37. 37.
    Olié V, Canonico M, Scarabin PY. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr Opin Hematol. 2010;17:457–63CrossRefGoogle Scholar
  38. 38.
    Sweetland S, Beral V, Balkwill A et al. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J. Thromb. Haemost. 2012;10:2277–86CrossRefGoogle Scholar
  39. 39.
    Birkhaeuser M, Hadji P, Imthurn B, Mueck AO, Neulen J, Thaler CJ, Wiegratz I, Wildt L. Postmenopausale Hormonsubstitution und Thrombo-Embolierisiko: Unterschied zwischen oraler und transdermaler Applikation? Gyne 2014Google Scholar
  40. 40.
    Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107:103–11CrossRefGoogle Scholar
  41. 41.
    Asi N, Mohammed K, Haydour Q, Gionfriddo MR, Vargas OL, Prokop LJ, Faubion SS, Murad MH. Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis. Syst Rev. 2016;26:121CrossRefGoogle Scholar
  42. 42.
    Kharode Y, Bodine PV, Miller CP et al. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology. 2008;149:6084–91CrossRefGoogle Scholar
  43. 43.
    Komm BS, Mirkin S. Evolution of the tissue selective estrogen complex (TSEC). J Cell Physiol}. 2013;228:1423–27CrossRefGoogle Scholar
  44. 44.
    Stefanopoulou E, Grunfeld EA. Mind-body interventions for vasomotor symptoms in healthy menopausal women and breast cancer survivors. A systematic review. J Psychosom Obstet Gynaecol. 2017;38(:210–25CrossRefGoogle Scholar
  45. 45.
    Newton KM, Reed SD, Guthrie KA, Sherman KJ, Booth-LaForce C, Caan B, Sternfeld B, Carpenter JS, Learman LA, Freeman EW, Cohen LS, Joffe H, Anderson GL, Larson JC, Hunt JR, Ensrud KE, LaCroix AZ. Efficacy of yoga for vasomotor symptoms: a randomized controlled trial. Menopause. 2014;21:339–46PubMedPubMedCentralGoogle Scholar
  46. 46.
    Reed SD, Guthrie KA, Newton KM, Anderson GL, Booth-LaForce C, Caan B, Carpenter JS, Cohen LS, Dunn AL, Ensrud KE, Freeman EW, Hunt JR, Joffe H, Larson JC, Learman LA, Rothenberg R, Seguin RA, Sherman KJ, Sternfeld BS, LaCroix AZ. Menopausal quality of life: RCT of yoga, exercise, and omega-3 supplements. Am J Obstet Gynecol. 2014;210:244, e1-11CrossRefGoogle Scholar
  47. 47.
    Broekmans FJ, Soules MR, Fauser BC. Ovarian Aging: Mechanisms and Clinical Consequences. Endocrine Reviews. 2009;30:465–93CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  • Corinna Mann
    • 1
    Email author
  • Sven Mahner
    • 2
  • Christian J. Thaler
    • 2
  1. 1.Hormon- und Kinderwunschzentrum, Klinik und Poliklinik für Frauenheilkunde und GeburtshilfeKlinikum der Ludwig Maximilians Universität München, Campus InnenstadtMünchenDeutschland
  2. 2.Klinik und Poliklinik für Frauenheilkunde und GeburtshilfeKlinikum der Ludwig-Maximilians-Universität MünchenMünchenDeutschland

Personalised recommendations